SCHEMBL457611

SCHEMBL457611

COc1ccc(NC(=S)NN=C2Nc3ccc([N+](=O)[O-])cc3C2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
MAPT P10636 8/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
GAA P10253 3/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
NPC1 O15118 2/20 0.44
HSP90AA1 P07900 1/20 0.44
PKM P14618 1/20 0.44
PAX8 Q06710 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
LMNA P02545 3/20 0.43
MAPK1 P28482 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
RECQL P46063 1/20 0.43
CAPN9 O14815 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457126 0.87 ALDH1A1 (0.51) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL469971 0.86 CA12 (0.49) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL455315 0.84 KDR (0.52) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL455908 0.83 RRM1 (0.44) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL457948 0.82 CES1 (0.47) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL456608 0.81 CYP1A2 (0.49) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL455700 0.81 ALDH1A1 (0.47) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL456020 0.77 LMNA (0.51) ALDH1A1MAPTSMN1; SMN2HTTMEN1
SCHEMBL469858 0.77 CA1 (0.54) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL457328 0.74 CES1 (0.50) ALDH1A1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed